Dyne Therapeutics (NASDAQ:DYN) Shares Down 4.7% - What's Next?

Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report)'s share price fell 4.7% on Thursday . The stock traded as low as $14.76 and last traded at $14.81. 109,639 shares were traded during mid-day trading, a decline of 95% from the average session volume of 2,353,063 shares. The stock had previously closed at $15.54.

Analysts Set New Price Targets

A number of research firms recently weighed in on DYN. Baird R W raised Dyne Therapeutics to a "strong-buy" rating in a research report on Thursday, December 12th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $45.00 price target on shares of Dyne Therapeutics in a research report on Tuesday. Piper Sandler reissued an "overweight" rating and set a $53.00 price objective on shares of Dyne Therapeutics in a research report on Monday, September 23rd. JPMorgan Chase & Co. cut shares of Dyne Therapeutics from an "overweight" rating to a "neutral" rating and decreased their target price for the stock from $43.00 to $35.00 in a report on Thursday, October 24th. Finally, Raymond James upgraded shares of Dyne Therapeutics to a "strong-buy" rating in a research note on Thursday, December 12th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, Dyne Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $49.91.

Dyne Therapeutics Stock Performance

The stock has a market capitalization of $1.44 billion, a P/E ratio of -3.97 and a beta of 1.16. The firm has a fifty day moving average price of $25.63 and a two-hundred day moving average price of $33.33.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last announced its earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($0.25). On average, research analysts anticipate that Dyne Therapeutics, Inc. will post -3.45 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Jason P. Rhodes sold 782 shares of Dyne Therapeutics stock in a transaction dated Thursday, November 14th. The stock was sold at an average price of $33.10, for a total transaction of $25,884.20. Following the transaction, the director now directly owns 15,962 shares of the company's stock, valued at $528,342.20. The trade was a 4.67 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Richard William Scalzo sold 1,455 shares of the stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $28.12, for a total transaction of $40,914.60. Following the completion of the sale, the senior vice president now directly owns 127,078 shares of the company's stock, valued at $3,573,433.36. This represents a 1.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 21,071 shares of company stock valued at $606,476 in the last 90 days. Company insiders own 20.77% of the company's stock.

Institutional Trading of Dyne Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. JPMorgan Chase & Co. increased its stake in Dyne Therapeutics by 4.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 101,750 shares of the company's stock worth $3,655,000 after buying an additional 4,236 shares in the last quarter. Virtue Capital Management LLC grew its position in shares of Dyne Therapeutics by 4.4% during the third quarter. Virtue Capital Management LLC now owns 23,208 shares of the company's stock worth $834,000 after purchasing an additional 981 shares in the last quarter. Geode Capital Management LLC raised its stake in Dyne Therapeutics by 4.8% during the 3rd quarter. Geode Capital Management LLC now owns 1,859,413 shares of the company's stock valued at $66,802,000 after purchasing an additional 84,760 shares during the period. Barclays PLC lifted its holdings in Dyne Therapeutics by 162.2% in the 3rd quarter. Barclays PLC now owns 207,309 shares of the company's stock worth $7,446,000 after purchasing an additional 128,246 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd bought a new position in Dyne Therapeutics in the 3rd quarter worth approximately $1,067,000. 96.68% of the stock is currently owned by institutional investors.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.